Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with Read More
Breast cancer is the most common cancer among women, with Read More
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the Article“These data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.”
Read the ArticleResearch showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the ArticleDr. Nathalie McDowell Johnson, M.D., FACS, surgical oncologist and immediate past president of the American Society of Breast Surgeons shares her opinion in STAT News article on why Black women with breast cancer experience higher death rates and how utilizing a more advanced genomic test can provide a more comprehensive understanding and accurate risk evaluation.
Read the ArticleNathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, recently spoke with HIT Consultant about why the conventional genomic test commonly used for breast cancer treatment planning is failing Black women, and in part, contributing to their disproportionately high mortality rate. Dr. Johnson discusses why MammaPrint provides more consistent results for Black women than the other gene expression profiling test, enabling more personalized treatment and improved outcomes.
Read the ArticleFierce Healthcare recently spoke with Nathalie Johnson, MD, FACS, President of The American Society of Breast Cancer Surgeons, about the need for more widespread use of advanced gene expression profiling tests that provide more consistent results for Black women with early-stage breast cancer. Dr. Johnson highlights how the standard of care today negatively impacts outcomes for Black women, and why it is essential for clinicians to switch to more sophisticated, unbiased tests, such as MammaPrint & BluePrint, to address key disparities in breast cancer care.
Read the Article